Cdc7-IN-1 |
| Catalog No.GC35628 |
Cdc7-IN-1 (Composé 13) est un inhibiteur très puissant, sélectif et compétitif de l'ATP de la kinase Cdc7, avec une valeur IC50 de 0,6 nM À 1 mM d'ATP et avec des caractéristiques de ralentissement lent. Cdc7-IN-1 inhibe puissamment l'activité de Cdc7 dans les cellules cancéreuses et induit efficacement la mort cellulaire.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1402055-25-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death[1]. IC50: 0.6 nM (Cdc7, at 1 mM ATP)[1]
[1]. Irie T, et al. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors. Eur J Med Chem. 2017 Apr 21;130:406-418.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *